Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
43 hedge funds and large institutions have $43.6M invested in Carisma Therapeutics in 2019 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 18 closing their positions.
1,501% more call options, than puts
Call options by funds: $2.48M | Put options by funds: $155K
126% more capital invested
Capital invested by funds: $19.3M → $43.6M (+$24.3M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
50% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 8
0.23% more ownership
Funds ownership: 1.21% → 1.43% (+0.23%)
10% less funds holding
Funds holding: 48 → 43 (-5)
28% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$12.1M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$1.96M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
+$1.88M |
| 4 |
KCM
Kingdon Capital Management
New York
|
+$1.39M |
| 5 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
+$299K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CHP
Castle Hook Partners
New York
|
-$1.3M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$258K |
| 3 |
State Street
Boston,
Massachusetts
|
-$151K |
| 4 |
BCM
BlueCrest Capital Management
St Helier,
Jersey
|
-$129K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$68K |
CARM Hedge Fund Activity: Q2 2019 in Review
43 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q2 2019, worth a combined $43.6M — up 126% from $19.3M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of CARM and 13 opened new positions — a net loss of 5 holders — while 8 trimmed existing stakes and 12 added.
The largest buyer was CVI Holdings, opening a new position worth an estimated $12.1M. The largest seller was Castle Hook Partners, exiting entirely with an estimated $1.3M sold.
- 43 institutional investors held Carisma Therapeutics (CARM) as of Q2 2019, down from 48 in Q1 2019.
- Funds reported $43.6M of Carisma Therapeutics stock for Q2 2019, up 126% quarter-over-quarter.
- 13 funds opened new Carisma Therapeutics positions in Q2 2019 and 18 closed out, a net change of -5 holders.
- The largest Carisma Therapeutics buyer in Q2 2019 was CVI Holdings, an estimated $12.1M added.
- The largest Carisma Therapeutics seller in Q2 2019 was Castle Hook Partners, an estimated $1.3M sold.
Based on aggregated 13F filings for Q2 2019.